RU2014124154A - Иммуногенные комплексы полианионных карбомеров и полипептидов env и способы их получения и применения - Google Patents
Иммуногенные комплексы полианионных карбомеров и полипептидов env и способы их получения и применения Download PDFInfo
- Publication number
- RU2014124154A RU2014124154A RU2014124154/15A RU2014124154A RU2014124154A RU 2014124154 A RU2014124154 A RU 2014124154A RU 2014124154/15 A RU2014124154/15 A RU 2014124154/15A RU 2014124154 A RU2014124154 A RU 2014124154A RU 2014124154 A RU2014124154 A RU 2014124154A
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- env
- env polypeptide
- immunogenic composition
- hiv
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract 68
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 68
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 68
- 229920002125 Sokalan® Polymers 0.000 title claims abstract 16
- 239000000203 mixture Substances 0.000 claims abstract 28
- 230000002163 immunogen Effects 0.000 claims abstract 25
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract 15
- 229960001631 carbomer Drugs 0.000 claims abstract 15
- 229920000642 polymer Polymers 0.000 claims abstract 15
- 229920000447 polyanionic polymer Polymers 0.000 claims abstract 12
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims abstract 5
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000002671 adjuvant Substances 0.000 claims abstract 4
- 230000028993 immune response Effects 0.000 claims 6
- 239000007764 o/w emulsion Substances 0.000 claims 2
- 210000004877 mucosa Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161559512P | 2011-11-14 | 2011-11-14 | |
| US61/559,512 | 2011-11-14 | ||
| PCT/US2012/065113 WO2013074696A1 (en) | 2011-11-14 | 2012-11-14 | Immunogenic complexes of polyanionic carbomers and env polypeptides and methods of manufacture and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014124154A true RU2014124154A (ru) | 2015-12-27 |
Family
ID=47222339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014124154/15A RU2014124154A (ru) | 2011-11-14 | 2012-11-14 | Иммуногенные комплексы полианионных карбомеров и полипептидов env и способы их получения и применения |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9393300B2 (https=) |
| EP (1) | EP2780035A1 (https=) |
| JP (1) | JP2014533290A (https=) |
| CN (1) | CN104271155A (https=) |
| AU (1) | AU2012340035A1 (https=) |
| BR (1) | BR112014011560A2 (https=) |
| CA (1) | CA2855826A1 (https=) |
| MX (1) | MX2014005548A (https=) |
| RU (1) | RU2014124154A (https=) |
| WO (1) | WO2013074696A1 (https=) |
| ZA (1) | ZA201402910B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US3790665A (en) | 1968-02-23 | 1974-02-05 | Haver Lockhart Labor Inc | Injectable adjuvant,method of preparing same and compositions including such adjuvant |
| US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
| US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| JPH0832637B2 (ja) * | 1985-02-14 | 1996-03-29 | アクゾ・エヌ・ヴエー | 合成免疫原 |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| ATE112687T1 (de) | 1988-09-13 | 1994-10-15 | Chiron Corp | Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen. |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5840313A (en) | 1990-09-27 | 1998-11-24 | Syntello Vaccine Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| EP0688205A1 (en) * | 1993-03-11 | 1995-12-27 | Secretech, Inc. | Polymeric mucoadhesives in the delivery of immunogens at mucosal surfaces |
| CN1111540C (zh) | 1993-06-09 | 2003-06-18 | 康诺特实验室有限公司 | 串联的合成hiv－1肽类 |
| US5741492A (en) | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| JP4776075B2 (ja) | 1998-12-31 | 2011-09-21 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 改変ｈｉｖｅｎｖポリペプチド |
| JP2006509039A (ja) * | 2002-12-03 | 2006-03-16 | ユニバーシティ オブ マサチューセッツ | 多価初代ｈｉｖ−１糖タンパク質ｄｎａワクチンおよびワクチン接種方法 |
| AU2006304725B2 (en) * | 2005-10-17 | 2012-03-15 | Novartis Ag | Multiclade HIV vaccines |
| JP2009536653A (ja) * | 2006-05-09 | 2009-10-15 | ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | Ｈｉｖ−１免疫原性組成物 |
| WO2011003138A1 (en) * | 2009-07-06 | 2011-01-13 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
-
2012
- 2012-11-14 CN CN201280055731.5A patent/CN104271155A/zh active Pending
- 2012-11-14 BR BR112014011560A patent/BR112014011560A2/pt not_active IP Right Cessation
- 2012-11-14 WO PCT/US2012/065113 patent/WO2013074696A1/en not_active Ceased
- 2012-11-14 JP JP2014541423A patent/JP2014533290A/ja active Pending
- 2012-11-14 MX MX2014005548A patent/MX2014005548A/es unknown
- 2012-11-14 AU AU2012340035A patent/AU2012340035A1/en not_active Abandoned
- 2012-11-14 RU RU2014124154/15A patent/RU2014124154A/ru not_active Application Discontinuation
- 2012-11-14 US US14/357,270 patent/US9393300B2/en not_active Expired - Fee Related
- 2012-11-14 CA CA2855826A patent/CA2855826A1/en not_active Abandoned
- 2012-11-14 EP EP12791061.0A patent/EP2780035A1/en not_active Withdrawn
-
2014
- 2014-04-22 ZA ZA2014/02910A patent/ZA201402910B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104271155A (zh) | 2015-01-07 |
| JP2014533290A (ja) | 2014-12-11 |
| US20140314703A1 (en) | 2014-10-23 |
| CA2855826A1 (en) | 2013-05-23 |
| US9393300B2 (en) | 2016-07-19 |
| WO2013074696A1 (en) | 2013-05-23 |
| MX2014005548A (es) | 2014-08-21 |
| BR112014011560A2 (pt) | 2017-05-09 |
| AU2012340035A1 (en) | 2014-04-17 |
| EP2780035A1 (en) | 2014-09-24 |
| ZA201402910B (en) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014124154A (ru) | Иммуногенные комплексы полианионных карбомеров и полипептидов env и способы их получения и применения | |
| JP2014533290A5 (https=) | ||
| CA2733898C (en) | Mosaic clade m env-based polyvalent hiv vaccine | |
| WO2021019102A3 (en) | A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes | |
| US20210353740A1 (en) | Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use | |
| Iyer et al. | Virus-like particles displaying trimeric simian immunodeficiency virus (SIV) envelope gp160 enhance the breadth of DNA/modified vaccinia virus Ankara SIV vaccine-induced antibody responses in rhesus macaques | |
| US11897919B2 (en) | Multivalent HIV vaccine boost compositions and methods of use | |
| Rosenkrands et al. | Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes | |
| EA201892233A1 (ru) | Композиции и способы, связанные с иммуногенами вич-1 | |
| JP2018505882A5 (https=) | ||
| Patel et al. | Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization | |
| JP2010539901A5 (https=) | ||
| RU2015100889A (ru) | Вакцины для менингококка серогруппы х | |
| Sundling et al. | CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization | |
| WO2012003234A3 (en) | Env trimer immunogens | |
| Wan et al. | As a genetic adjuvant, CTA improves the immunogenicity of DNA vaccines in an ADP-ribosyltransferase activity-and IL-6-dependent manner | |
| CN102258779A (zh) | 四种及四种以上hiv载体基因疫苗序贯及重复应用 | |
| Hargrave et al. | Infection and Vaccine Development | |
| US20170107260A1 (en) | Mosaic hiv-1 sequences and uses thereof | |
| RU2015115520A (ru) | Рекомбинантная вакцина для профилактики вирусного гепатита В (Варианты) | |
| WO2025006577A3 (en) | Compositions for prevention of cardiomyopathy syndrome | |
| RU2011124695A (ru) | Способ получения специфического иммуномодулятора | |
| Montagnier | AIDS Research: An historical survey and perspectives | |
| Wang et al. | Rising epidemic of HIV-1 infections among general populations in Fujian, China | |
| Yoshida | Atazanavir/emtricitabine/tenofovir disoproxil fumarate/ritonavir |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170407 |